-
公开(公告)号：US20050049281A1
公开(公告)日：2005-03-03
申请号：US10866078
申请日：2004-06-14
申请人： Andreas Huth , Martin Krueger , Ludwig Zorn , Stuart Ince , Rolf Bohlmann , Karl Thierauch , Andreas Menrad , Martin Haberey , Holger Hess-Stumpp
发明人： Andreas Huth , Martin Krueger , Ludwig Zorn , Stuart Ince , Rolf Bohlmann , Karl Thierauch , Andreas Menrad , Martin Haberey , Holger Hess-Stumpp
IPC分类号： A61K31/444 , C07D211/84 , C07D213/62
CPC分类号： C07D213/64
摘要： Novel VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridones and their use as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis are selected.
摘要翻译： 选择新型VEGFR-2和VEGFR-3抑制性邻氨基苯甲酰胺吡啶酮及其作为用于治疗由持续性血管生成引发的疾病的药物的用途。
-
公开(公告)号：US20070135489A1
公开(公告)日：2007-06-14
申请号：US11654643
申请日：2007-01-18
申请人： Andreas Huth , Martin Krueger , Ludwig Zorn , Stuart Ince , Rolf Bohlmann , Karl Thierauch , Andreas Menrad , Martin Haberey , Holger Hess-Stumpp
发明人： Andreas Huth , Martin Krueger , Ludwig Zorn , Stuart Ince , Rolf Bohlmann , Karl Thierauch , Andreas Menrad , Martin Haberey , Holger Hess-Stumpp
IPC分类号： A61K31/444 , A61K31/4412 , C07D213/62
CPC分类号： C07D213/64
摘要： Novel VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridones and their use as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis are selected.
摘要翻译： 选择新型VEGFR-2和VEGFR-3抑制性邻氨基苯甲酰胺吡啶酮及其作为用于治疗由持续性血管生成触发的疾病的药物的用途。
-
公开(公告)号：US07202260B2
公开(公告)日：2007-04-10
申请号：US10866078
申请日：2004-06-14
申请人： Andreas Huth , Martin Krueger , Ludwig Zorn , Stuart Ince , Rolf Bohlmann , Karl Heinz Thierauch , Andreas Menrad , Martin Haberey , Holger Hess-Stumpp
发明人： Andreas Huth , Martin Krueger , Ludwig Zorn , Stuart Ince , Rolf Bohlmann , Karl Heinz Thierauch , Andreas Menrad , Martin Haberey , Holger Hess-Stumpp
IPC分类号： C07D401/01 , C07D213/02 , A61K31/44
CPC分类号： C07D213/64
摘要： Novel VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridones and their use as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis are selected.
摘要翻译： 选择新型VEGFR-2和VEGFR-3抑制性邻氨基苯甲酰胺吡啶酮及其作为用于治疗由持续性血管生成引发的疾病的药物的用途。
-
公开(公告)号：US20060116380A1
公开(公告)日：2006-06-01
申请号：US11265517
申请日：2005-11-03
申请人： Rolf Bohlmann , Martin Haberey , Andreas Huth , Stuart Ince , Martin Krueger , Karl-Heinz Thierauch , Holger Hess-Stumpp , Andreas Reichel
发明人： Rolf Bohlmann , Martin Haberey , Andreas Huth , Stuart Ince , Martin Krueger , Karl-Heinz Thierauch , Holger Hess-Stumpp , Andreas Reichel
IPC分类号： A61K31/506 , A61K31/501 , A61K31/4709 , A61K31/497 , A61K31/444 , C07D403/14 , C07D401/14
CPC分类号： C07D401/12
摘要： The invention relates to novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors, their production and use as pharmaceutical agents for preventing or treating diseases that are triggered by persistent angiogenesis.
-
5.发明申请Novel anthranilamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors 失效新型邻氨基苯甲酰胺吡啶脲作为血管内皮生长因子（VEGF）受体激酶抑制剂公开(公告)号：US20060264425A1
公开(公告)日：2006-11-23
申请号：US11265516
申请日：2005-11-03
申请人： Rolf Bohlmann , Martin Haberey , Andreas Huth , Stuart Ince , Martin Krueger , Karl-Heinz Thierauch , Holger Hess-Stumpp
发明人： Rolf Bohlmann , Martin Haberey , Andreas Huth , Stuart Ince , Martin Krueger , Karl-Heinz Thierauch , Holger Hess-Stumpp
IPC分类号： A61K31/541 , A61K31/5377 , A61K31/496 , C07D417/14 , C07D413/14 , C07D403/14
CPC分类号： C07D213/75 , C07D401/12 , C07D401/14 , C07D491/10
摘要： The invention relates to novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors, their production and use as pharmaceutical agents for preventing or treating diseases that are triggered by persistent angiogenesis.
摘要翻译： 本发明涉及作为VEGF受体激酶抑制剂的新型邻氨基苯甲酰胺吡啶脲，其作为用于预防或治疗由持续血管生成引发的疾病的药剂的生产和用途。
-
6.发明授权Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors 失效烟酰胺吡啶脲作为血管内皮生长因子（VEGF）受体激酶抑制剂公开(公告)号：US07906533B2
公开(公告)日：2011-03-15
申请号：US11262953
申请日：2005-11-01
申请人： Rolf Bohlmann , Martin Haberey , Andreas Huth , Stuart Ince , Martin Krueger , Karl-Heinz Thierauch , Holger Hess-Stumpp
发明人： Rolf Bohlmann , Martin Haberey , Andreas Huth , Stuart Ince , Martin Krueger , Karl-Heinz Thierauch , Holger Hess-Stumpp
IPC分类号： A61K31/4439 , C07D401/14
CPC分类号： C07D403/14
摘要： The invention relates to novel nicotinamide pyridinureas as VEGF receptor kinase inhibitors, their production and use as pharmaceutical agents for preventing or treating diseases that are triggered by persistent angiogenesis.
摘要翻译： 本发明涉及作为VEGF受体激酶抑制剂的新型烟酰胺吡啶脲，其作为预防或治疗由持续性血管生成引发的疾病的药剂的生产和用途。
-
7.发明授权Anthranilamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors 失效邻氨基苯甲酰胺吡啶脲作为血管内皮生长因子（VEGF）受体激酶抑制剂公开(公告)号：US07902229B2
公开(公告)日：2011-03-08
申请号：US11265517
申请日：2005-11-03
申请人： Rolf Bohlmann , Martin Haberey , Andreas Huth , Stuart Ince , Martin Krueger , Karl-Heinz Thierauch , Holger Hess-Stumpp , Andreas Reichel
发明人： Rolf Bohlmann , Martin Haberey , Andreas Huth , Stuart Ince , Martin Krueger , Karl-Heinz Thierauch , Holger Hess-Stumpp , Andreas Reichel
IPC分类号： A61K31/4439 , C07D401/12
CPC分类号： C07D401/12
摘要： The invention relates to novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors, their production and use as pharmaceutical agents for preventing or treating diseases that are triggered by persistent angiogenesis.
摘要翻译： 本发明涉及作为VEGF受体激酶抑制剂的新型邻氨基苯甲酰胺吡啶脲，其作为用于预防或治疗由持续血管生成引发的疾病的药剂的生产和用途。
-
8.发明申请Novel nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors 失效新型烟酰胺吡啶脲作为血管内皮生长因子（VEGF）受体激酶抑制剂公开(公告)号：US20060160861A1
公开(公告)日：2006-07-20
申请号：US11262953
申请日：2005-11-01
申请人： Rolf Bohlmann , Martin Haberey , Andreas Huth , Stuart Ince , Martin Krueger , Karl-Heinz Thierauch , Holger Hess-Stumpp
发明人： Rolf Bohlmann , Martin Haberey , Andreas Huth , Stuart Ince , Martin Krueger , Karl-Heinz Thierauch , Holger Hess-Stumpp
IPC分类号： A61K31/444 , A61K31/4439 , C07D403/14
CPC分类号： C07D403/14
摘要： The invention relates to novel nicotinamide pyridinureas as VEGF receptor kinase inhibitors, their production and use as pharmaceutical agents for preventing or treating diseases that are triggered by persistent angiogenesis.
摘要翻译： 本发明涉及作为VEGF受体激酶抑制剂的新型烟酰胺吡啶脲，其作为预防或治疗由持续性血管生成引发的疾病的药剂的生产和用途。
-
9.发明授权Anthranilamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors 失效邻氨基苯甲酰胺吡啶脲作为血管内皮生长因子（VEGF）受体激酶抑制剂公开(公告)号：US07572794B2
公开(公告)日：2009-08-11
申请号：US11265516
申请日：2005-11-03
申请人： Rolf Bohlmann , Martin Haberey , Andreas Huth , Stuart James Ince , Martin Krueger , Karl-Heinz Thierauch , Holger Hess-Stumpp
发明人： Rolf Bohlmann , Martin Haberey , Andreas Huth , Stuart James Ince , Martin Krueger , Karl-Heinz Thierauch , Holger Hess-Stumpp
IPC分类号： A61K31/535 , A61K31/47 , C07D413/00 , C07D211/80
CPC分类号： C07D213/75 , C07D401/12 , C07D401/14 , C07D491/10
摘要： The invention relates to novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors, their production and use as pharmaceutical agents for preventing or treating diseases that are triggered by persistent angiogenesis.
摘要翻译： 本发明涉及作为VEGF受体激酶抑制剂的新型邻氨基苯甲酰胺吡啶脲，其作为用于预防或治疗由持续血管生成引发的疾病的药剂的生产和用途。
-
10.发明授权11&bgr; LONG-CHAIN SUBSTITUTED ESTRATRIENES, METHOD FOR THEIR PRODUCTION, PHARMACEUTICAL PREPARATIONS CONTAINING SAID 11&bgr; LONG-CHAIN SUBSTITUTED ESTATRIENES, AND THEIR USE FOR PRODUCING MEDICAMENTS 失效11β长链取代的ESTRATRIENES，其生产方法，含有11β长链取代的ESTATRIRIES的药物制剂及其用于生产药物的用途公开(公告)号：US06790842B1
公开(公告)日：2004-09-14
申请号：US10018429
申请日：2002-05-07
申请人： Rolf Bohlmann , Nikolaus Heinrich , Jorg Kroll , Gerhard Sauer , Karl-Heinrich Fritzemeier , Christa Hegele-Hartung , Jens Hoffmann , Rosemarie Lichtner , Ludwig Zorn
发明人： Rolf Bohlmann , Nikolaus Heinrich , Jorg Kroll , Gerhard Sauer , Karl-Heinrich Fritzemeier , Christa Hegele-Hartung , Jens Hoffmann , Rosemarie Lichtner , Ludwig Zorn
IPC分类号： A61K3158
CPC分类号： C07J1/00
摘要： This invention describes a 11&bgr;-long-chain-substituted estratriene of general formula (I), in which R11 is a long-chain radical that has a nitrogen atom and optionally a sulfur atom, which in addition can be functionalized in the terminal position with a perfluoroalkyl group or an optionally substituted arly radical. The compound can have antiestrogenic or tissue-selective estrogenic properties and be suitable for the production of pharmaceutical agents.
摘要翻译： 本发明描述了通式（I）的11b-长链取代的雌三烯，其中R 11是具有氮原子和任选的硫原子的长链基团，其还可以在 具有全氟烷基或任选取代的芳基的末端位置。 该化合物可以具有抗雌激素或组织选择性雌激素特性，并且适用于生产药剂。
-
-
-
-
-
-
-
-
-
搜索结果
94 条记录 (耗时 0.037 秒)
